Evenity
| Chemical Name | romosozumab-aqqg |
| Dosage Form | Injectable (subcutaneous; 105 mg/1.17 mL) |
| Drug Class | Monoclonal antibodies |
| System | Musculoskeletal |
| Company | Amgen Inc. |
| Approval Year | 2019 |
Indication
- Evenity is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.